Researchers based at the Dana-Farber Cancer Institute in Boston, USA along with others from the Journal of the National Cancer Institute have found addition of oxaliplatin treatment options for colon cancer increases survival rate. Our Canadian pharmacy agrees with a retrospective analysis conducted by these institutes. Survival is a major issue with complicated diseases like cancer, and researchers are on the lookout for new drugs capable of decreasing mortality rate. People buy Xeloda as standard option with intravenous 5 fluorouracil/leucovorin (i.v. 5-FU/LV) for post-surgery adjuvant colon cancer. Adding oxaliplatin to the medical regimen affords tremendous benefits to patients otherwise suffering from a highly fatal disease.
Reduced Hospital Visits a Major Benefit
Researchers found patient visits reduced by over 60% when oxaliplatin was also prescribed for treatment as compared to normal therapy used for post-surgery patients with colon cancer. Quality of life improved substantially, as patients were able to lead a normal life with less visits to the hospital. Oral medication was another benefit to be considered.
Clinical trials proved Xeloda could be safely used as first-line monotherapy for treatment of colon cancer leading to metastasis. The medication has already proved effective for treatment of metastatic breast cancer, especially in cases where intravenous chemotherapy has to be initiated to arrest progress of the disease and if a patient exhibits drug resistance with other prescription drugs.
Clinical Trials Prove Survival Rates Increase By Over 75% with Definite Population Sample
Overall survival rate measured for a population sample over a period of three years showed a definite group of people including young patients had a much higher survival rate with the new treatment option. Our Canadian pharmacy was impressed with the higher percentage fluctuation between 79 to 88% with the help of the optimum population sample. Clinical trials conducted under controlled conditions yielded a higher 86% survival rate with the help of the combination regimen. Metastasis at stage III colon cancer could be controlled better when medication was offered to a definite group of people who were healthier, younger, and belonged to a definite race or clan.
Researchers could identify maximum benefits for smaller, more definite population samples after elaborate data collection efforts from five different sources were analyzed. Records from the New York State Cancer Registry (NYSCR); National Comprehensive Cancer Network; Surveillance Epidemiology and End Results Registry Linked Through Medicare Records; Cancer Care Outcomes Research And Surveillance Consortium; and NYSCR link to Medicaid were considered for analysis.
The sample population generally consisted of patients below the age of 74 years diagnosed with stage III colon cancer. Post-diagnosis surgery was conducted within 90 days, and adjuvant chemotherapy was sustained for a period of 120 days after surgery. Sub groups included in the metastasic colon cancer study sample demonstrated the same positive results. Researchers found a slightly higher survival rate existing in the white community as compare to racial or interracial communities. Our generic Canadian pharmacy is convinced minor adjustments done to isolate best-case results for the general population can be derived from further research using findings from the present study.